Anumana Revenue and Competitors

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway.\n\nSerious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments.\n\nAnumana recently acquired NeuTrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With nference’s proprietary nSights real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making.\n\nAnumana’s 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.